Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;1512(1):5-9.
doi: 10.1111/nyas.14764. Epub 2022 Mar 1.

Disruptive innovation in psychiatry

Jerome Sarris  1   2   3
Affiliations

Disruptive innovation in psychiatry

Jerome Sarris. Ann N Y Acad Sci. 2022 Jun.

Abstract

Disruptive innovation is a cornerstone of various disciplines, particularly in the business world, where paradigm-altering approaches are often lauded. As a construct, disruptive psychiatry can be considered to embody such an approach by the pursuit of innovations within the field which test boundaries and shake up the status quo. Given the importance of addressing the current mental health pandemic, and the deficit of highly effective pharmacological treatments for various conditions, innovative disruptive thinking is required. Significant promise exists via the provision of potentially more effective innovative therapeutic options, including digital interventions, psychedelic medicines, microbiome-altering treatments, brain stimulation technology, and nanotechnology-based delivery systems. These approaches may be further advanced by individualization of the treatments using computational technology (including quantum computing, machine learning, and artificial intelligence) and genomics.

Keywords: computational psychiatry; disruptive innovation; microbiome; nanotechnology; psychedelics; quantum computing.

PubMed Disclaimer

Conflict of interest statement

J.S. has received honoraria, research support, royalties, or consultancy or travel grant funding from: Psychae Institute (a not‐for‐profit that studies psychedelic medicines, receiving funding from commercial entities to conduct research), Integria Healthcare & MediHerb, Pfizer, Scius Health, Key Pharmaceuticals, Taki Mai, FIT‐BioCeuticals, GrunBiotics, Blackmores, SPRIM, Soho‐Flordis, Healthworld, HealthEd, HealthMasters, Elsevier, Chaminade University, International Society for Affective Disorders, Complementary Medicines Australia, Global Pharma Solutions, Terry White Chemists, ANS, Society for Medicinal Plant and Natural Product Research, Sanofi‐Aventis, Omega‐3 Centre, Medical Research Future Fund, the National Health and Medical Research Council, and a CR Roper Fellowship.

References

    1. Adaji, A. 2018. Integrated care: a disruptive innovation for extending psychiatric expertise to primary care practices. Mayo Clin. Proc. Innov. Qual. Outcomes 2: 99–102. - PMC - PubMed
    1. Perkins, D. , Sarris J., Rossell S., et al. 2021. Medicinal psychedelics for mental health and addiction: advancing research of an emerging paradigm. ANZ J. Psychiatry 55: 1127–1133. - PubMed
    1. Carhart‐Harris, R. , Giribaldi B., Watts R., et al. 2021. Trial of psilocybin versus escitalopram for depression. N. Engl. J. Med. 384: 1402–1411. - PubMed
    1. Galvão‐Coelho, N. , Marx W., Gonzalez M., et al. 2021. Classic serotonergic psychedelics on mood and depressive symptoms: a systematic review and meta‐analysis. Psychopharmacology 238: 341–354. - PMC - PubMed
    1. Mitchell, J.M. , Bogenschutz M., Lilienstein A., et al. 2021. MDMA‐assisted therapy for severe PTSD: a randomized, double‐blind, placebo‐controlled phase 3 study. Nat. Med. 27: 1025–1033. - PMC - PubMed

Publication types